EQ101 Phase 2 study in alopecia areata is fully enrolled with topline data expected in Q2 2024
EQ302, an orally delivered multi-cytokine inhibitor of IL-15 & IL-21, will be advanced in place of.
21.12.2023 - Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced an update on multi-cytokine programs EQ101 in development for the . Seite 1